Application of L858R+V834L gene mutation primary tumor transplantation tumor model for human non-small cell lung cancer

Abstract

The invention discloses application of an L858R+V834L gene mutation primary tumor transplantation tumor model for a human non-small cell lung cancer. A transplantation tumor generated by the L858R+V834L gene mutation primary tumor transplantation tumor model for the human non-small cell lung cancer can be restrained by Iressa; the L858R+V834L gene mutation primary tumor transplantation tumor model provided by the invention can be used for screening a targeted drug for treating an EGRF (estimated glomerular filtration rate) mutation positive patient suffered from the non-small cell lung cancer; and an experimental technical platform is provided for the deep exploration of the action of epidermal growth factor receptor (EGFR) mutation generated in the non-small cell lung cancer.

Description

Technical field: [0001] The present invention relates to the pharmaceutical industry, in particular to the application of a human non-small cell lung cancer L858R+V834L gene mutation primary tumor xenograft model in the screening of targeted drugs for the treatment of EGRF mutation-positive patients with non-small cell lung cancer, and to explore epidermal growth The role of factor receptor (EGFR) mutations in the occurrence of non-small cell lung cancer provides an experimental technology platform. Background technique: [0002] The incidence of mutations in the EGFR tyrosine kinase region of non-small cell lung cancer patients in my country is about 30%. The mutations mainly occur in exons 19 and 21, which account for 54.5% and 40.3% of the total number of mutations. Among them, the 858th codon of exon 21 undergoes a base substitution (T→G) mutation, which makes the amino acid at this position in the EGFR protein change from leucine (L) to arginine (R), referred to as L858R mut...

AI Technical Summary

Problems solved by technology

Although there are a few cell lines with two EGFR L858R mutations in the world, no L858R+V834L double gene mutation cell line has been seen so far.

And it is currently believed that although tumor cell lines are practical, reproducible, and easy to operate, the consistency between the treatment results of these models and the clinical results of patients is not good, mainly because only a very small number of primary tumors can form cell lines, and their Growth as monolayers does not reflect the microenvironment of human tumors and responds equally to therapy in vivo, and these tumors grown in vitro represent a group of patients with a poorer clinical prognosis, necessitating the need for additional clinically relevant non-small cell NSCLC models of lung cancer and their application in clinical trials

Images